These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35339715)

  • 1. Analysis of efficacy and safety of linezolid-based chemotherapeutic regimens for patients with postoperative multidrug-resistant spinal tuberculosis.
    Qiao J; Yang L; Feng J; Dai X; Xu F; Xia P
    Int J Infect Dis; 2022 May; 118():264-269. PubMed ID: 35339715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of linezolid on serum PCT, ESR, and CRP in patients with pulmonary tuberculosis and pneumonia.
    Ding RD; Zhang HJ
    Medicine (Baltimore); 2018 Sep; 97(37):e12177. PubMed ID: 30212947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis.
    Li Y; Huang H; Dong W; Lan T; Fan J; Wen S; Zhang T; Qin S; Guo A
    PLoS One; 2019; 14(10):e0223391. PubMed ID: 31581274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective study of tolerability and efficacy of linezolid in patients with multidrug-resistant tuberculosis (1998-2014).
    Ramírez-Lapausa M; Pascual Pareja JF; Carrillo Gómez R; Martínez-Prieto M; González-Ruano Pérez P; Noguerado Asensio A
    Enferm Infecc Microbiol Clin; 2016 Feb; 34(2):85-90. PubMed ID: 26015067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.
    Agyeman AA; Ofori-Asenso R
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):41. PubMed ID: 27334498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice.
    Zhao W; Guo Z; Zheng M; Zhang J; Wang B; Li P; Fu L; Liu S
    Int J Antimicrob Agents; 2014 Feb; 43(2):148-53. PubMed ID: 24290060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid for patients with multidrug-resistant tuberculosis/extensively drug-resistant tuberculosis in China.
    Zhang P; Tan J; Lin Y; Zhang H; Deng G; Chen X
    Drug Discov Ther; 2022 May; 16(2):96-98. PubMed ID: 35444071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of Linezolid in Tuberculosis Lesions in Patients with Spinal Multidrug-Resistant Tuberculosis.
    Li Y; Dong W; Lan T; Fan J; Qin S; Guo A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China.
    Fang MT; Su YF; An HR; Zhang PZ; Deng GF; Liu HM; Mao Z; Zeng JF; Li G; Yang QT; Wang ZY
    BMC Infect Dis; 2021 Sep; 21(1):1015. PubMed ID: 34583653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linezolid for the treatment of multidrug-resistant tuberculosis.
    Fortún J; Martín-Dávila P; Navas E; Pérez-Elías MJ; Cobo J; Tato M; De la Pedrosa EG; Gómez-Mampaso E; Moreno S
    J Antimicrob Chemother; 2005 Jul; 56(1):180-5. PubMed ID: 15911549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    ; Ahmad N; Ahuja SD; Akkerman OW; Alffenaar JC; Anderson LF; Baghaei P; Bang D; Barry PM; Bastos ML; Behera D; Benedetti A; Bisson GP; Boeree MJ; Bonnet M; Brode SK; Brust JCM; Cai Y; Caumes E; Cegielski JP; Centis R; Chan PC; Chan ED; Chang KC; Charles M; Cirule A; Dalcolmo MP; D'Ambrosio L; de Vries G; Dheda K; Esmail A; Flood J; Fox GJ; Fréchet-Jachym M; Fregona G; Gayoso R; Gegia M; Gler MT; Gu S; Guglielmetti L; Holtz TH; Hughes J; Isaakidis P; Jarlsberg L; Kempker RR; Keshavjee S; Khan FA; Kipiani M; Koenig SP; Koh WJ; Kritski A; Kuksa L; Kvasnovsky CL; Kwak N; Lan Z; Lange C; Laniado-Laborín R; Lee M; Leimane V; Leung CC; Leung EC; Li PZ; Lowenthal P; Maciel EL; Marks SM; Mase S; Mbuagbaw L; Migliori GB; Milanov V; Miller AC; Mitnick CD; Modongo C; Mohr E; Monedero I; Nahid P; Ndjeka N; O'Donnell MR; Padayatchi N; Palmero D; Pape JW; Podewils LJ; Reynolds I; Riekstina V; Robert J; Rodriguez M; Seaworth B; Seung KJ; Schnippel K; Shim TS; Singla R; Smith SE; Sotgiu G; Sukhbaatar G; Tabarsi P; Tiberi S; Trajman A; Trieu L; Udwadia ZF; van der Werf TS; Veziris N; Viiklepp P; Vilbrun SC; Walsh K; Westenhouse J; Yew WW; Yim JJ; Zetola NM; Zignol M; Menzies D
    Lancet; 2018 Sep; 392(10150):821-834. PubMed ID: 30215381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo.
    Zhao W; Zheng M; Wang B; Mu X; Li P; Fu L; Liu S; Guo Z
    Int J Infect Dis; 2016 Nov; 52():23-28. PubMed ID: 27613365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid in the treatment of multidrug-resistant tuberculosis.
    Schecter GF; Scott C; True L; Raftery A; Flood J; Mase S
    Clin Infect Dis; 2010 Jan; 50(1):49-55. PubMed ID: 19947856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?
    Chang KC; Yew WW; Cheung SW; Leung CC; Tam CM; Chau CH; Wen PK; Chan RC
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3445-9. PubMed ID: 23650165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
    Brown AN; Drusano GL; Adams JR; Rodriquez JL; Jambunathan K; Baluya DL; Brown DL; Kwara A; Mirsalis JC; Hafner R; Louie A
    mBio; 2015 Nov; 6(6):e01741-15. PubMed ID: 26530386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of
    Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.